Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

We are pleased to share the April 2025 issue of Wilson Sonsini's Sustainability and ESG Advisory Practice Update. Each issue combines news, key ...

Bionxt Solutions is preparing for a pilot clinical trial to test its sublingual formulation of cladribine to treat multiple ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The health sector is navigating various challenges, including debates over drug pricing in the EU, pest agreements between ...